Cyclacel Phar Pr SEC Filings

Kua Khai Loon, a director of Cyclacel Pharmaceuticals, Inc., reported initial beneficial ownership after a securities purchase agreement dated June 20, 2025. He directly acquired 218,000 shares of the company's common stock and received three tranches of common stock purchase warrants (Series A, B and C), each exercisable to purchase 218,000 shares. Each warrant became exercisable on 06/20/2025 and expires on 06/20/2030 with exercise prices of $7.65, $9.00, and $10.20, respectively. The filing states the 4.99% beneficial ownership limitation under each warrant was removed on 09/01/2025. The Form 3 indicates the reporting person filed as an individual and is identified as a director.

Cyclacel Pharmaceuticals, Inc. director Yap Kim Choy filed an Initial Statement of Beneficial Ownership (Form 3) disclosing an acquisition tied to a June 20, 2025 securities purchase agreement. Mr. Yap acquired 218,000 shares of common stock and received three separate warrant series (Series A, B and C), each to purchase 218,000 shares. The warrants became exercisable on 06/20/2025 and expire 06/20/2030 with exercise prices of $7.65, $9.00 and $10.20, respectively. A beneficial ownership limitation of 4.99% under each warrant was removed on 09/01/2025. The Form 3 lists Mr. Yap as a director and reports direct ownership of the disclosed securities.

Cyclacel Pharmaceuticals, Inc. Schedule 13G filed by Yap Kim Choy discloses beneficial ownership of 218,000 shares, representing 9.8% of the class. The filing states these shares are held with sole voting and dispositive power and that they were not acquired to change or influence control of the issuer. The statement identifies the filing as a Schedule 13G disclosure and includes a signature certifying the accuracy of the information.

Cyclacel Pharmaceuticals, Inc. Schedule 13G filed by Ong Yee Lung reports beneficial ownership of 218,000 shares of Cyclacel common stock, representing 9.8% of the class. The filer states sole voting and dispositive power over all 218,000 shares. The filing is submitted under Schedule 13G disclosures and includes a certification that the shares were not acquired to change or influence control of the issuer. Several items (group membership, holdings on behalf of others, and subsidiary/group identification) are marked Not Applicable.

Kua Khai Loon filed a Schedule 13G reporting beneficial ownership of 218,000 shares of Cyclacel Pharmaceuticals, Inc. common stock, representing 9.8% of the class. The filing shows sole voting and dispositive power over all 218,000 shares and classifies the filer as an individual (IN). The document states the securities were not acquired to change or influence control of the issuer. The filing includes issuer and filer addresses and the CUSIP 23254L876. The signature date on the filing is 08/18/2025 and the triggering event date is 07/28/2025.

Cyclacel Pharmaceuticals reporting persons Armistice Capital, LLC and Steven Boyd state they do not beneficially own any shares of Cyclacel common stock. The filing discloses 0 shares and 0% ownership, and explains that Armistice Capital acts as investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. The statement clarifies that the Master Fund disclaims beneficial ownership because it lacks voting and dispositive power under its investment management agreement, while Armistice and Mr. Boyd may be deemed to possess voting and investment power through that agreement. The ownership percentages are calculated using 1,583,965 shares reported outstanding in the issuer's S-1.